Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 1

Status

Terminated 3Completed 2

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 2Gastrointestinal 1

Conditions

Head and Neck Neoplasms 2Neoplasms, Squamous Cell 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

pembrolizumab 73Carboplatin 60Cyclophosphamide 59Nivolumab 52Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 36Rituximab 32Capecitabine 32Bevacizumab 29Docetaxel 28fludarabine 27atezolizumab 26Cytarabine 26avelumab 24venetoclax 23Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23Azacitidine 23Ipilimumab 22Fluorouracil 22Temozolomide 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × zalutumumab × Clear all
NCT00707655 2023-08-03

Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy

Genmab

Phase 1/2 Terminated
8 enrolled 10 charts
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00677924 2023-07-18

GEN206

Genmab

Phase 1/2 Terminated
9 enrolled 8 charts
Gastrointestinal

Colorectal Neoplasms

NCT00401401 2011-12-23

Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer

Genmab

Phase 1/2 Terminated
30 enrolled 13 charts
Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡